<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="192055">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592306</url>
  </required_header>
  <id_info>
    <org_study_id>ATG in Lung Transplantation</org_study_id>
    <nct_id>NCT00592306</nct_id>
  </id_info>
  <brief_title>Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation</brief_title>
  <official_title>A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to take a population of lung transplant recipients who meet
      UCLA criteria for induction chemotherapy with thymoglobulin and prospectively study weather
      giving the first dose intraoperatively versus postoperatively makes a difference with how
      patients do during and after lung transplantation. In addition, these cohorts will be
      compared to patients who do not qualify for thymoglobulin and receive either an alternative
      agent or no agent. The primary endpoint is primary graft dysfunction. We will also evaluate
      several other early and late end points such as ventilator days, ICU/hospital days,
      acute/chronic rejection, infection, CT chest abnormalities, and survival.

      We will also collect donor lung tissue and lavage fluid for measurement of various proteins
      and receptor expression at two time points: (1) prior to implementation and dosing of
      induction chemotherapy and (2) after transplantation (following a course of induction
      chemotherapy). This will allow us to possibly make a connection between the profiles of the
      various proteins and receptors and the clinical outcomes, depending on weather the patient
      has received induction chemotherapy, starting intraoperatively or postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Graft Dysfunction</measure>
    <time_frame>paO2/FiO2 ratio at post transplant, 24 hr, and 48 hr time points</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>We plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabbit antithymocyte globulin + placebo</intervention_name>
    <description>All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + rabbit antithymocyte globulin</intervention_name>
    <description>All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  On a voluntary basis, all patients eligible for bilateral lung transplantation
             between the ages of 18-65 years (inclusive)

        Exclusion Criteria:

          -  Have any known allergy to horse or rabbit antithymocyte polyclonal agents

          -  Have a preoperative platelet count less then 100,000/mm3

          -  Are recipients of multiple organ transplants (either simultaneous or sequential)

          -  Are recipients of a single lung transplantation

          -  Have a contraindication to rabbit antithymocyte globulin based on judgement of the
             investigators (i.e. bleeding diathesis or overwhelming risk of intense
             immunosuppression) including the following patients: greater than 65 years of age,
             prior diagnosis of malignancy (with the exception skin malignancies), underlying
             suppurative lung disease (i.e. bronchiectasis, cystic fibrosis, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajan Saggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pulmonology and Critical Care at David Geffen School of Medicine at UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajan Saggar, M.D.</last_name>
    <phone>310-825-5635</phone>
    <email>rsaggar@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michaela Dyke</last_name>
    <phone>310-825-5635</phone>
    <email>mdyke@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajan Saggar, M.D.</last_name>
      <phone>310-825-5635</phone>
      <email>rsaggar@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Dyke</last_name>
      <phone>310-825-5635</phone>
      <email>mdyke@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajan Saggar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David J Ross, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Belperio, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph P Lynch, III, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abbas Ardehali, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Kubak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajeev Saggar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam Weigt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aric Gregson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <lastchanged_date>June 4, 2008</lastchanged_date>
  <firstreceived_date>December 28, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Rajan Saggar</name_title>
    <organization>David Geffen School of Medicine, UCLA</organization>
  </responsible_party>
  <keyword>ATG</keyword>
  <keyword>rabbit thymoglobulin</keyword>
  <keyword>reperfusion lung injury</keyword>
  <keyword>primary graft dysfunction</keyword>
  <keyword>lung transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
